Mon 12/18/2017 03:54 ET
DJIA24651.74143.080.58%SOLAR24.530.050.20%GOLD1258.201.130.09%Shanghai3136.7734.501.10%
S&P 5002675.8123.810.89%BANKS27.810.381.37%OIL57.340.300.52%Nikkei22420.08417.011.86%
NASDAQ6936.5879.771.15%SEMI99.251.601.61%US/EU1.180.000.17%Futures2689.757.750.29%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Sage Therapeutics Inc. - SAGE)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add SAGE
  
From: blacksheep (Rep: 307) reply to singhtelecomDate: 12/07/2017 07:43
Forum: Wall Street Pit - Msg #2705290 - List SAGE msgs Thread #673943721 (Rec: 0)
Re: Quite a wise investment
Sage Therapeutics' SAGE-217 successful in mid-stage MDD study; shares ahead 52% premarket

Dec. 7, 2017 7:18 AM ET|About: Sage Therapeutics (SAGE)|By: Douglas W. House, SA News Editor
Sage Therapeutics (NASDAQ:SAGE) is up 52% premarket on light volume in response to its announcement of positive results from a Phase 2 clinical trial assessing SAGE-217 for the treatment of adult patients with moderate-to-severe major depressive disorder (MDD), a Fast Track indication in the U.S.

The 89-subject study met its primary endpoint of a statistically significant average reduction in HAM-D score from baseline to day 15 (p<0.0001) versus placebo. HAM-D is a rating scale for depression. At day 15, 64% of patients in the treatment group achieved remission compared to 23% for placebo (p=0.0005). Other secondary endpoints were also met.

SAGE-217 was generally well-tolerated with no serious or severe adverse events observed. The most common adverse events were headache, dizziness, nausea and drowsiness.

Management will host a conference call this morning at 8:00 am ET to discuss the results.

SAGE-217, a neuroactive steroid, is next-generation GABA modulator. The GABA system, the major inhibitory signaling pathway in the brain and central nervous system (CNS), plays a key role in regulating CNS function. The company intends to advance the program into Phase 3 development.


someone bought in the money 1000 calls NOV 75 at 18 bucks



Reply to singhtelecom - Msg #56 - 08/04/2017 10:27

someone bought in the money 1000 calls NOV 75 at 18 bucks
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser blacksheep: Reward | Watch | IgnoreSAGE: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add SAGE
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.